New for AAPS 2016, MicroFLUX and MacroFLUX testing technology give developers reliable absorption data

for APIs, formulations and finished dosage products

Billerica, MA, USA – Pharmaceutical scientists have long sought a reliable method for

predicting the absorption potential of finished dosage products prior to clinical trials, but have been frustrated by the limitations of standard dissolution testing, which cannot predict the in vivo response to drug products due to the complex interplay of solubility and permeability in the human body. Now, for the first time, new FLUX testing technology from Pion combines traditional dissolution testing with a repeatable method for assessing the absorption potential of APIs, API/ingredient combinations, or finished dosage products. The result is a single combined test that makes more reliable and realistic IVIVC (in vitro-in vivo correlation) testing and modeling possible.

The FLUX testing technology consists of a traditional USP I or II s